| Literature DB >> 32651166 |
Ilaria Marigo1, Rosalinda Trovato2, Francesca Hofer3, Vincenzo Ingangi4, Giacomo Desantis4, Kevin Leone4, Francesco De Sanctis3, Stefano Ugel3, Stefania Canè3, Anna Simonelli3, Alessia Lamolinara5, Manuela Iezzi5, Matteo Fassan6, Massimo Rugge6, Federico Boschi7, Giulia Borile8,9, Thomas Eisenhaure10, Siranush Sarkizova10, David Lieb10, Nir Hacohen10, Luca Azzolin11, Stefano Piccolo11,12, Rita Lawlor13, Aldo Scarpa13,14, Luisa Carbognin15, Emilio Bria15, Silvio Bicciato16, Peter J Murray17, Vincenzo Bronte2.
Abstract
Tumor-associated macrophages (TAM) are regulators of extracellular matrix (ECM) remodeling and metastatic progression, the main cause of cancer-associated death. We found that disabled homolog 2 mitogen-responsive phosphoprotein (DAB2) is highly expressed in tumor-infiltrating TAMs and that its genetic ablation significantly impairs lung metastasis formation. DAB2-expressing TAMs, mainly localized along the tumor-invasive front, participate in integrin recycling, ECM remodeling, and directional migration in a tridimensional matrix. DAB2+ macrophages escort the invasive dissemination of cancer cells by a mechanosensing pathway requiring the transcription factor YAP. In human lobular breast and gastric carcinomas, DAB2+ TAMs correlated with a poor clinical outcome, identifying DAB2 as potential prognostic biomarker for stratification of patients with cancer. DAB2 is therefore central for the prometastatic activity of TAMs. SIGNIFICANCE: DAB2 expression in macrophages is essential for metastasis formation but not primary tumor growth. Mechanosensing cues, activating the complex YAP-TAZ, regulate DAB2 in macrophages, which in turn controls integrin recycling and ECM remodeling in 3-D tissue matrix. The presence of DAB2+ TAMs in patients with cancer correlates with worse prognosis.This article is highlighted in the In This Issue feature, p. 1611. ©2020 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32651166 DOI: 10.1158/2159-8290.CD-20-0036
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397